Current Treatment Options in Neurology

, Volume 6, Issue 6, pp 489–498 | Cite as

Menstrual migraine

  • Lisa K. Mannix
  • Anne H. Calhoun
Article

Opinion statement

The initial treatment of menstrual migraine (MM) should be the same as that of migraine that occurs at any other time during the month and should include lifestyle modifications and the use of appropriate acute therapies aimed at decreasing attack symptoms, duration, and disability. If results of acute therapy are incomplete or unsatisfactory, then preventive strategies may be required. Comorbidities may, however, influence choice of preventive therapy or accelerate initiation of preventive therapy. Comorbid dysmenorrhea, menometrorrhagia, and endometriosis argue for early use of hormonal therapies. Hormonal strategies may be appropriate because the premenstrual decline in estradiol concentration predictably precipitates MM, and targeting and preventing this decline can decrease headache occurrence. Continuous combined hormonal contraceptives can reduce hormone fluctuations and, for some MM sufferers, can deliver more than contraceptive benefits. Nonsteroidal anti-inflammatory drugs are appropriate for treatment of co-occurring dysmenorrhea or when hormonal strategies are contraindicated; their efficacy may be caused partly by the role of prostaglandins in MM and dysmenorrhea. As with the use of hormonal therapy, use of nonsteroidal anti-inflammatory drugs allows for treatment of breakthrough headache with triptans. Results of clinical trials suggest that daily use of triptans in the menstrual window may bring about as much as 50% reduction in headache frequency, but such use still requires acute treatment of breakthrough headache and adherence to daily triptan limits. Use of this strategy requires that headache occurrence be highly predictable.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Silberstein SD, Merriam GR: Sex hormones and headache. J Pain Symptom Manage 1993, 8:243–259.CrossRefGoogle Scholar
  2. 2.
    Lipton RB, Stewart WF, Diamond S, et al.: Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001, 41:646–657.PubMedCrossRefGoogle Scholar
  3. 3.
    Bille BS: Migraine in school children. A study of the incidence and short-term prognosis, and a clinical, psychological and electroencephalographic comparison between children with migraine and matched controls. Acta Paediatr 1962, 51(suppl 136):1–151.Google Scholar
  4. 4.
    Waters WE: Epidemiology of headache and migraine in women. J Neurol Neurosurg Psychiatry 1971, 34:148–153.PubMedCrossRefGoogle Scholar
  5. 5.
    Stewart WF, Lipton RB, Celentano DD, Reed ML: Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992, 267:64–69.PubMedCrossRefGoogle Scholar
  6. 6.
    Epstein MT, Hockaday JM, Hockaday TD: Migraine and reporoductive hormones throughout the menstrual cycle. Lancet 1975, 1:543–548.PubMedCrossRefGoogle Scholar
  7. 7.
    Neri I, Granella F, Nappi R, et al.: Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas 1993, 17:31–37.PubMedCrossRefGoogle Scholar
  8. 8.
    Lay CL, Newman LC: Menstrual migraine: approaches to management. CNS Drugs 1999, 12:189–195.CrossRefGoogle Scholar
  9. 9.
    Launer LJ, Terwindt GM, Ferrari MD: The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999, 53:537–542.PubMedGoogle Scholar
  10. 10.
    Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004, 24 (suppl 1):9–160.Google Scholar
  11. 11.
    Edelson RN: Menstrual migraine and other hormonal aspects of migraine. Headache 1985, 25:376–379.PubMedCrossRefGoogle Scholar
  12. 12.
    Couturier EG, Bomhof MA, Neven AK, van Duijn NP: Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia 2003, 23:302–308.PubMedCrossRefGoogle Scholar
  13. 13.
    Stewart WF, Lipton RB, Chee E, et al.: Menstrual cycle and headache in a population sample of migraineurs. Neurology 2000, 55:1517–1523.PubMedGoogle Scholar
  14. 14.
    Schoenen J, Sawyer J: Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. Cephalalgia 1997, 17(suppl 18):28–40.PubMedGoogle Scholar
  15. 15.
    Salonen R, Saiers J: Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analysis. Cephalalgia 1999, 19:16–19.PubMedCrossRefGoogle Scholar
  16. 16.
    Silberstein SD, Massiou H, Le Jeunne C, et al.: Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol 2000, 96:237–242.PubMedCrossRefGoogle Scholar
  17. 17.
    Loder E: Prophylaxis of menstrual migraine with triptans: problems and possibilities. Neurology 2002, 59:1677–1681. This is a well-considered discussion of pitfalls and possibilities associated with daily use of triptans in migraine management.PubMedGoogle Scholar
  18. 18.
    Paiva T, Farinha A, Martins A, et al.: Chronic headaches and sleep disorders. Arch Intern Med 1997, 157:1701–1705.PubMedCrossRefGoogle Scholar
  19. 19.
    Baker FC, Driver HS: Self-reported sleep across the menstrual cycle in young, healthy women. J Psychosom Res 2004, 56:239–243.PubMedCrossRefGoogle Scholar
  20. 20.
    Hollander LE, Freeman EW, Sammel MD, et al.: M. Sleep quality, estradiol levels, and behavioral factors in late reproductive age women. Obstet Gynecol 2001, 98:391–397.PubMedCrossRefGoogle Scholar
  21. 21.
    Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. The American Academy of Neurology. Available at: http://www.ahsnet.org/guidelines.php. Accessed June, 2004. This website provides the Review of American Academy of Neurology guidelines for acute treatment of migraine.Google Scholar
  22. 22.
    Lipton RB, Stewart WF, Ryan RE Jr, et al.: Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol Feb 1998, 55:210–217.CrossRefGoogle Scholar
  23. 23.
    Silberstein SD, Lipton RB, Goadsby PJ, eds: Headache in Clinical Practice. Oxford: ISIS Medical Media; 1998Google Scholar
  24. 24.
    Silberstein S, Tepper S, Brandes J, et al.: Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 2004, 62:1552–1557.PubMedGoogle Scholar
  25. 25.
    Rapoport AM, Sheftell FD: Headache Disorders: A management Guide for Practitioners. Philadelphia: WB Saunders Company; 1996.Google Scholar
  26. 26.
    Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD: The triptan formulations: how to match patients and products. CNS Drugs 2003, 17:431–447.PubMedCrossRefGoogle Scholar
  27. 27.
    Axert [prescribing information]. Raritan, NJ: Ortho-McNeil Pharmaceutical Inc.; 2003Google Scholar
  28. 28.
    Imitrex [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2004Google Scholar
  29. 29.
    Zomig [prescribing information]. Wilmington, DE: Astra-Zeneca Pharmaceuticals; 2003Google Scholar
  30. 30.
    Maxalt [prescribing information]. Whitehouse Station, NJ: Merck & Co.,Inc; 2003.Google Scholar
  31. 31.
    Frova [prescribing information]. Craigavon, United Kingdom: Galen, Limited; 2001.Google Scholar
  32. 32.
    Amerge [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2003Google Scholar
  33. 33.
    Relpax [prescribing information]. New York, NY: Pfizer; 2003.Google Scholar
  34. 34.
    Nett R, Landy S, Shackelford S, Richardson MS, et al.: Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. Obstet Gynecol 2003, 102:835–842. This is a prospective study of oral sumatriptan in migraine management.PubMedCrossRefGoogle Scholar
  35. 35.
    Silberstein S: The efficacy of zolmitriptan is unaffected by the relationship to menses. Paper presented at the 10th Congress of the International Headache Society. New York, NY; June 20–July 2, 2001.Google Scholar
  36. 36.
    Loder E, Silberstein SD, Abu-Shakra S, et al.: Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache 2004, 44:120–130. This is a prospective study of efficacy and tolerability of oral zolmitriptan in migraine management.PubMedCrossRefGoogle Scholar
  37. 37.
    Massiou H, Silberstein S, Le Jeunne C, et al.: Efficacy of rizatriptan in menstrual migraine: Freedom from pain and associated symptoms at 2-h and 24-h sustained pain-free status. Cephalalgia 2000, 20:343–344.Google Scholar
  38. 38.
    Silberstein SD, Massiou H, McCarroll KA, Lines CR: Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. Headache 2002, 42:917–923.PubMedCrossRefGoogle Scholar
  39. 39.
    MacGregor EA, Keywood C: Frovatriptan is effective in menstrually associated migraine (abstract). Cephalalgia 2000, 20:338–357.CrossRefGoogle Scholar
  40. 40.
    Hettiarachi J, Pitei D: Oral Eletriptan is effective in treating menstrually-associated migraine and women on oral contraceptives or hormone replacement therapy. Paper presented at: 42nd Meeting of the American Headache Society. Montreal, Canada; 2002.Google Scholar
  41. 41.
    Sances G, Martignoni E, Fioroni L, et al.: Naproxen sodium in menstrual migraine prophylaxis: a doubleblind placebo controlled study. Headache 1990, 30:705–709.PubMedCrossRefGoogle Scholar
  42. 42.
    Von Seggern RL, Mannix LK, Adelman JU: Rofecoxib in the prevention of perimenstrual migraine: an openlabel pilot trial. Headache 2004, 44:160–165.CrossRefGoogle Scholar
  43. 43.
    Newman LC, Lipton RB, Lay CL, Solomon S. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology 1998;51:307–309.PubMedGoogle Scholar
  44. 44.
    Newman LC, Mannix LK, Sandy S, et al.: Naratriptan as short-term prophylaxis of menstrually-associated migraine: A randomized, double-blind, placebo-controlled study. Headache 2001, 41:248–256. This is a prospective study of the use of naratriptan in shortterm prophylaxis of migraine management.PubMedCrossRefGoogle Scholar
  45. 45.
    Brandes JL, Smith T: Naratriptan 1 mg BID in the prophylactic treatment of menstrually-associated migraine. Paper presented at the 44th Annual Meeting of the American Headache Society. Seattle, WA; June 18–22, 2002.Google Scholar
  46. 46.
    Savani N, Loftus J, Mansbach H, Scot A: A randomised, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1 mg twice daily as prophylactic treatment for menstrually-associated migraine. Paper presented at the 6th European Headache Congress. Istanbul, Turkey; June 17–22, 2002.Google Scholar
  47. 47.
    Nett R, Mannix L, Sandy S, et al.: Randomized, doubleblind, placebo-controlled parallel group evaluation of oral naratriptan 1 mg twice daily as prophylactic treatment for menstrually-associated migraine. Paper presented at the 55th Annual Meeting of the American Academy of Neurology. Honolulu, HI; March 29–April 5, 2003.Google Scholar
  48. 48.
    Silberstein SD, Elkind AH, Schreiber C: Frovatriptan, a selective HT1B/1D agonist, is effective for prophylaxis of menstrually associated migraine (abstract). Neurology 2003, 60(Suppl 1):A94.Google Scholar
  49. 49.
    Smith T, Nett R: Frovatriptan is well tolerated during repeated use for prophylaxis of menstrually associated migraine (abstract). Headache 2003, 43:586.Google Scholar
  50. 50.
    Spierings ELH, Couch R, Blumenthal HJ: Clinical characteristics of menstrually associated migraine: a review of results from a study of the use of frovatriptan for prophylaxis of menstrually associated migraine (abstract). Neurology 2003, 60(suppl 1):A493.Google Scholar
  51. 51.
    Tepper S, Freitag F: Prophylactic use of frovatriptan for menstrually associated migraine is effective and does not cause rebound migraine in the postdosing period (abstract). Headache 2003, 43:585.CrossRefGoogle Scholar
  52. 52.
    Goldstein J, Ninan M, Rapoport AM: The safety and tolerability of frovatriptan, a selective 5HT1B/1D agonist, used for prophylaxis of menstrually associated migraine (abstract). Neurology 2003, 60 (Suppl 1):A494.Google Scholar
  53. 53.
    Singer R, Schim J: Frovatriptan for prophylaxis of menstrually associated migraine: efficacy and tolerability in patients using oral contraceptives compared to nonusers (abstract). Headache 2003, 43:587.Google Scholar
  54. 54.
    Calhoun A: Four hypotheses for understanding menstrual migraine. The Female Patient 2004, 29:38–44. This is a comprehensive current review of the theories about menstrual migraine and their relevance to clinical management of these headaches.Google Scholar
  55. 55.
    WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996, 348:498–505.CrossRefGoogle Scholar
  56. 56.
    Petitti DB, Sidney S, Bernstein A, et al.: Stroke in users of low-dose oral contraceptives. N Engl J Med 1996, 335:8–15.PubMedCrossRefGoogle Scholar
  57. 57.
    Chan WS, Ray J, Wai EK, et al.: Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern Med 2004, 164:741–747.PubMedCrossRefGoogle Scholar
  58. 58.
    Calhoun AH: Migraine and menopause. Headache 2004, 44:106.PubMedCrossRefGoogle Scholar
  59. 59.
    Facchinetti F, Sances G, Borella P, et al.: Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991, 31:298–301.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Lisa K. Mannix
    • 1
  • Anne H. Calhoun
  1. 1.Headache AssociatesWest ChesterUSA

Personalised recommendations